 Home > Biochemical Engineering > Polypeptide > Cagrilintide for Sale > Cagrilintide is a long-acting amylin analogue regulate appetite control centers, enhancing satiety, slowing gastric

Cagrilintide is a long-acting amylin analogue regulate appetite control centers, enhancing satiety, slowing gastric

Name: Cagrilintide is a long-acting amylin analogue regulate appetite control centers, enhancing satiety, slowing gastric
Brand: focuses
SKU: pr2508291489
Price: 1 USD
Availability: InStock

66 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1415456-99-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

ningbo

Brand:

focuses

Packaging:

as requires

Price valid (until):

2025-09-29

Contact Supplier

 Chat Now

Fujian Genohope Biotech Ltd.

Company Type:

Manufactory

Location:

China

Payment Terms:

TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

Average Lead Time:

2 days

Qualification:

Main Products:

Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Product Detail

Cagrilintide is a long-acting amylin analogue, chemically modified to extend its half-life, enabling once-weekly subcutaneous administration. Its mechanism of action involves mimicking natural amylin to regulate appetite control centers, enhancing satiety, slowing gastric emptying, and thereby reducing food intake. It is primarily used for obesity treatment and is currently in Phase III clinical trials. When combined with semaglutide, it demonstrates synergistic effects for enhanced weight loss efficacy.

Source：chemical synthesis

Molecular weight: 4409.01

Molecular formula: C₁₉₄H₄₁₂N₅₉O₅₉S₂

CAS Number: 1415456-99-3

Storage conditions：Sealed,protected from light, -20℃±5℃

Manufacturing Process: Chemical synthesis

Mechanism of action: Cagrilintide is a long-acting amylin analogue, chemically modified to extend its half-life, enabling once-weekly subcutaneous administration. Its mechanism of action involves mimicking natural amylin to regulate appetite control centers, enhancing satiety, slowing gastric emptying, and thereby reducing food intake. It is primarily used for obesity treatment and is currently in Phase III clinical trials. When combined with semaglutide, it demonstrates synergistic effects for enhanced weight loss efficacy.

Structure：{Eicosanedioic acid-γ-Glu1}-Lys2-Cys3-Asn4-Thr5-Ala6-Thr7-Cys8-Ala9-Thr10-Gln11-Arg12-Leu13-Ala14-Glu15-Phe16-Leu17-Arg18-His19-Ser20-Ser21-Asn22-Asn23-Phe24-Gly25-Pro26-Ile27-Leu28-Pro29-Pro30-Thr31-Asn32-Val33-Gly34-Ser35-Asn36-Thr37-Pro38-NH2 (Disulfide bridge: Cys3-Cys8)

PRODUCT ADVANTAGES

GMP System is complied with both China NMPA and US FDA.
Stable quality: During mass production, with batch size over kg grade, the quality can be assured to be stable in successive productions, and the quality between batches has minor difference, which shows stable quality.
Fully synthesized, high purity.low impurities
Price: Most competitive pricing in the market
Support: The experienced team provides supports of full-life stages, including R&D, manufacturing, registration and commercialization in the peptide industries.

Our Factory

Fujian Genohope Biotech Ltd was established in 2019, It was co-founded by New Hope Hosencare Brothers and Taiwan Genovior Biotech Corporation. The company is located in the national "Cross-Strait Biotechnology and Health and Medical Industry Cooperation Zone" in Putian City, Fujian Province. The company has 260 employees, and in 2023, the company was selected as a Specialized in special innovative enterprises in Fujian Province.

The company focuses on High potency polypeptide API/solution, and sells polypeptide API/solution and preparation production services to the global market. The company covers a total area of 55 mu, with a total construction area of about 70,000 square meters, and has built about 800 square meters of R & D center, 1,000 square meters of quality control center and 3,300 square meters of GMP production workshop. At present, 13 production lines have been built, including 7 production lines for the preparation of recombinant peptide API and fully synthetic peptide API and 6 lines for injections. In addition, the company also has a large anti-tumor injection workshop, a small multi-purpose injection workshop, a large multi-purpose injection workshop. The construction and operation management of the production line meet the regulatory requirements of the global drug market and meet the double registration and declaration of China and the United States. Also can meet the customer registration and sales at home and abroad.

Product superiority：

At present, the company's main products are Semaglutide, Tirzepatide, Retatrutide, cosmetic medicine microspheres, collagen. In particular, the company has the advantage of mature 2 processes preparation of Semaglutide API, Semaglutide API registered in the US FDA (DMF No. : 040957),Tirzepatide API registered in the US FDA (DMF No. : 040503),

Semaglutide API has the following three characteristics: low price, high quality, and large production capacity (tonnage). Tirzepatide API is well received favourable reviews in the pharmaceutical industry of polypeptide .

Our Certificate

FAQ

Q: What does semaglutide do to your body?

A: Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy.

Q: What is the dark side of semaglutide?

A: Pancreatitis (swelling of the pancreas) may occur while you are using this medicine. Check with your doctor right away if you have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.

Q: Who cannot take semaglutide?

A: Thyroid cancer or if someone in your family had thyroid cancer. An unusual or allergic reaction to semaglutide, other medications, foods, dyes, or preservatives. Pregnant or trying to get pregnant. Breast-feeding.

Q: Why do I feel so bad on semaglutide?

A: However, semaglutide also affects the gastrointestinal tract by increasing the amount of glucagon. This has two effects on the digestive tract. First, it slows down the movement of food through your gut, which can lead to nausea, vomiting, and diarrhea.

Q: Can semaglutide be harmful?

A: Nausea, vomiting, and diarrhea are the most common semaglutide side effects. But they usually subside after a few weeks of using the medication. Although rare, serious side effects are possible. Some may require immediate medical attention, such as pancreatitis and allergic reactions.

Q: Can semaglutide damage your pancreas?

A: Does Semaglutide Damage Your Pancreas? Semaglutide has been associated with pancreatitis, which is an inflammation of the pancreas. While pancreatitis can cause damage to the pancreas, the occurrence of this side effect due to semaglutide is considered uncommon.

Q: Can I lose 50 lbs on semaglutide?

A: According to clinical trials, people on a weekly semaglutide dosage can expect to lose an average of 5–10% of their body weight. Patients who were overweight lost 5.9% of their body weight after three months of weekly semaglutide injections. The average weight loss was 10.9% after 6 months of weekly injections.

Q: Is metformin as good as semaglutide?

A: Between these two medications, semaglutide produces more significant weight loss than metformin, but metformin tends to be a more affordable option. But patients can also opt to combine these drugs to maximize their effects with a proper treatment plan.

ECHEMI Editorial Reference

Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

Basic Info

Product Name:
Cagrilintide

Other Name:
‌Cagrilitide、Cagrilintide acetate、Caglitide、Kagliptin、Cargliptin、Cargilinitide

CAS No.:
1415456-99-3

Molecular Formula:
C194H312N54O59S2

Molecular Weight:
0

EC Number:
206-141-6

Color/Form:
White to off-white

Categories:
Polypeptide

Research

Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

Status:
Investigational — Phase 3 (REDEFINE program, CagriSema combination)

Mechanism:
A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.

Activity note:
Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

Source:
MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

Clinical Development:
NCT05249895; NCT05249882

References

PubChem:
PubChem

Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation

Disclaimer:
Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Seller Information

Business Type:
Manufactory

Main Products:
Semaglutide,Tirzepatide,Retatrutide,Liraglutide,Cagrilintide,PLLA facial Implant

Location:
NO.288,Renyang, Binglun Village, Hushi Town, Xiuyu DistrictPutian City, Fujian Province 351146, China (CHN)

Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
2 days

Total Annual Revenue:
$25 million-$50 million

Total Employees:
201-300

Year of Establishment:
2019

Company Certificates
- DMF ACKNOWLEDGEMENT
- Notice of GMP Compliance Inspection
Company Profile

Fujian Genohope Biotech Ltd., is founded by New Hope Group, a Fortune Global 500 company, together with Genovior, fomous Taiwan peptide company and now a member of the Polaris Pharma Group, as the globalized center for R&D and production of peptide products, located in the National Biotech and Health Industry Zone of Across-Strait in Putian City, Fujian Province.

The company focuses on the research and development and production of high potency polypeptide products, targeting the global market, and provides polypeptide API/raw material and preparation products. It has built polypeptide API workshops, bio-fermentation workshops, polypeptide purification and lyophilization workshops, and multifunctional injection workshops that meet the GMP requirements of mainstream markets such as the U.S. FDA, EU EMA, Japanese PMDA, and China NMPA. With the strong support of New Hope Group, the company has introduced advanced large-scale CS-PREP® industrial preparative liquid chromatography systems, becoming one of the few polypeptide companies in the industry with a capacity of tons.

In 2023, Genehope has been rewarded as Specialized and Novel Enterprise of Fujian Province.
In 2023 June, the US FDA completed its first on-site inspection for Genohope.

Inquiry History

66 Inquiries

Country	Product	Purchase Quantity	Date Posted
United States	Cagrilintide	20 MG	Sep 30, 2026
Australia	Cagrilintide	20 MG	Aug 17, 2026
United Kingdom	Cagrilintide	10 MG	Jul 31, 2026
France	Cagrilintide	10 MG	May 22, 2026
Australia	Cagrilintide	4 MT	Mar 9, 2026
United States	Cagrilintide	15 MG	Feb 25, 2026
United States	Cagrilintide	10 PCS	Dec 27, 2025
United States	Cagrilintide	2 MT	Dec 21, 2025
United States	Cagrilintide	100 MG	Oct 28, 2025
United States	cagrilintide	2 MT	Aug 8, 2025
Philippines	Retatrutide	5 MG	Aug 5, 2025
China	Cagrilintide	100 G	May 6, 2025
United States	cagrilintide	5 MG	Feb 18, 2025
United States	Cagrilintide	3 MT	Feb 7, 2025
United States	Cagrilintide	100	Nov 12, 2024
United States	Cagrillintide Lyophilized powder	100 MG	Jul 4, 2024
United States	Cagrillintide Lyophilized powder	1000 MG	Apr 20, 2024
United States	Cagrilintide	10 MG	Sep 23, 2026
United States	Cagrilintide	25 MG	Aug 31, 2026
United States	Cagrlintide	1 MT	Jul 31, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Cagrilintide \| Cagrilintide White Powder Weight Loss peptide CAS 1415456-99-3 Jack	Pharmaceutical/99	$5/UNIT FOB	HUATAI PEPTIDES	Inquiry
Cagrilintide Peptide 50mg 100mg Raw Powder CAS 1415456-99-3 Support Custom Package Factory Bulk Supply	Reagent Grade/99.9	$30/UNIT FOB	Yixin Biotechnology Co., Ltd.	Inquiry
Cagrilintide Raw Material	Pharmaceutical Grade/99.92	$750-770/G EXW	Hong Kong JuXing Biotechnology Co limited	Inquiry
Hot Sale cagrilintide--Fast shipping Support customization, wholesale price, Lower price hot	Pharmaceutical Grade/99	$90-100/MT FOB	Jinan Zhiwenxinsheng Electric Technology Co., Ltd.	Inquiry
hot selling with best price Peptide Lyophilized Powder	Pharmaceutical Grade/99	$32-38/KG FOB	Peraya	Inquiry

Cagrilintide is a long-acting amylin analogue regulate appetite control centers, enhancing satiety, slowing gastric

Product Description

Seller Information

Inquiry History

Our Factory

Our Certificate

More Choices Find All Products for Sale 

Related Searches

More from this Seller